Gain TherapeuticsGANX
About: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
Employees: 32
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
151% more capital invested
Capital invested by funds: $3.89M [Q2] → $9.77M (+$5.88M) [Q3]
5.52% less ownership
Funds ownership: 12.08% [Q2] → 6.56% (-5.52%) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
32% less funds holding
Funds holding: 28 [Q2] → 19 (-9) [Q3]
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Roth MKM Boobalan Pachaiyappan 0% 1-year accuracy 0 / 5 met price target | 340%upside $7 | Buy Maintained | 24 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 118 / 313 met price target | 403%upside $8 | Buy Reiterated | 25 Nov 2024 |